Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
300 participants
OBSERVATIONAL
2025-10-01
2026-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Objectives. Primary: Compare the diagnostic accuracy (area under the ROC curve, AUROC) of SVV vs PVI for predicting fluid responsiveness to a small crystalloid bolus during laparoscopic major abdominal surgery.
Key secondary objectives: (1) determine optimal decision thresholds and report sensitivity, specificity, predictive values, and likelihood ratios; (2) compare calibration and classification performance (Youden index, net reclassification); (3) assess effect modification by pneumoperitoneum status, body mass index, ventilation parameters, and vasoactive use; (4) describe peri-bolus hemodynamic changes.
Design and setting. Prospective, single-center, paired diagnostic-accuracy cohort. Adults undergoing elective laparoscopic major abdominal surgery under general anesthesia are enrolled. Each participant undergoes up to two standardized 250-mL crystalloid fluid challenges delivered over \~3 minutes at two time points when feasible: (A) before insufflation and (B) after establishment of pneumoperitoneum at a hemodynamic steady state. Because both indices are recorded around the same fluid challenges, each participant serves as his/her own control.
Index tests. SVV (from the arterial pressure monitor) and PVI (from the pulse-oximetry monitor) are captured immediately before ("pre-bolus") and at \~3 minutes after each bolus. Index values are recorded by trained research staff and kept masked from anesthesia clinicians to avoid influencing usual care.
Reference standard and definition of fluid responsiveness. The reference standard is change in stroke volume index (SVI) or cardiac index derived from arterial pulse contour analysis. Fluid responsiveness is defined a priori as a ≥10% increase in SVI after the 250-mL bolus. Sensitivity analyses will use a 15% threshold and will repeat analyses with cardiac index. If signal quality is inadequate or a clinical safety concern arises, the test is aborted and data flagged.
Anesthesia and peri-bolus standardization. Ventilation is volume-controlled with tidal volume \~6-8 mL/kg predicted body weight and PEEP according to institutional practice; settings and pneumoperitoneum pressure/position are recorded. Vasoactive drugs and additional fluids are allowed as clinically indicated but are time-stamped; fluid challenges for research are not given when active titration of vasoactives makes a stable baseline impossible.
Participants. Inclusion: adults (≥18 years), ASA I-III, elective laparoscopic major abdominal surgery, arterial line in place, informed consent. Exclusion: clinically significant arrhythmia (e.g., atrial fibrillation with irregular R-R), severe valvular disease, intracardiac shunts, pregnancy, severe right-heart failure, inability to obtain reliable arterial or plethysmographic waveforms, or any condition in which a fluid challenge is judged unsafe by the anesthesiologist.
Outcomes. Primary outcome: AUROC of SVV vs PVI for predicting fluid responsiveness. Secondary outcomes: sensitivity/specificity at prespecified thresholds (e.g., SVV 12-13%, PVI 13-15%), decision-curve analysis, subgroup AUROC by pneumoperitoneum status, and immediate hemodynamic responses (MAP, HR).
Sample size and power. The study plans to enroll \~300 adults, yielding up to \~600 evaluable fluid challenges. Assuming a fluid-responsive rate of \~40%, this sample provides \>80% power to detect a paired AUROC difference of \~0.08-0.10 between SVV and PVI at α=0.05 using DeLong's test with clustering by subject.
Statistical analysis. ROC curves for SVV and PVI are constructed using clustered bootstrap resampling at the patient level (≥2000 replicates). AUROCs are compared with paired DeLong tests. Threshold performance metrics include exact 95% CIs with patient-clustered bootstrap. Mixed-effects logistic regression (random intercept for patient) will estimate adjusted odds of fluid responsiveness per unit change of each index; prespecified covariates include pneumoperitoneum status, BMI, tidal volume per kg, PEEP, and vasoactive use. Missing index or reference values are minimized; if \>5% are missing, multiple imputation will be performed in sensitivity analyses. All analyses follow a prespecified statistical analysis plan.
Safety and risk/benefit. Risks relate to small fluid boluses (transient blood pressure or heart-rate changes, fluid accumulation in vulnerable patients). The bolus is withheld or stopped for any safety concern. No experimental drugs or investigational devices are used; all monitors are standard of care. Participants are unlikely to benefit directly, but the results may improve future intraoperative fluid management.
Confidentiality and data handling. Data are captured on a secure electronic case-report form with coded identifiers. Only the research team has access. Results will be presented in aggregate without personal identifiers and disseminated in peer-reviewed venues.
Regulatory status. This is not an FDA-regulated drug or device investigation and is conducted under institutional review board approval at a single academic hospital in the Republic of Korea.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Laparoscopic Surgery Cohort
Adults undergoing elective laparoscopic major abdominal surgery under general anesthesia at a single academic hospital. Each participant may receive up to two standardized 250-mL crystalloid fluid challenges (pre- and post-pneumoperitoneum). SVV and PVI are recorded around each bolus; no assignment or experimental treatment.
Stroke Volume Variation (SVV) monitoring
Non-investigational physiologic monitoring. SVV derived from the invasive arterial pressure waveform using a commercially available platform. Used as an index test; values recorded immediately before and \~3 minutes after a standardized 250-mL crystalloid bolus at up to two time points (pre- and post-pneumoperitoneum). Readings are masked to clinicians; operation per usual care.
Pleth Variability Index (PVI) monitoring
Non-investigational pulse-oximetry-derived index. PVI obtained from a commercial monitor. Used as a paired index test; values recorded immediately before and \~3 minutes after each 250-mL crystalloid bolus (up to two time points). Readings masked; monitor used within standard care.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Stroke Volume Variation (SVV) monitoring
Non-investigational physiologic monitoring. SVV derived from the invasive arterial pressure waveform using a commercially available platform. Used as an index test; values recorded immediately before and \~3 minutes after a standardized 250-mL crystalloid bolus at up to two time points (pre- and post-pneumoperitoneum). Readings are masked to clinicians; operation per usual care.
Pleth Variability Index (PVI) monitoring
Non-investigational pulse-oximetry-derived index. PVI obtained from a commercial monitor. Used as a paired index test; values recorded immediately before and \~3 minutes after each 250-mL crystalloid bolus (up to two time points). Readings masked; monitor used within standard care.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ASA physical status I-III
* Elective laparoscopic major abdominal surgery under general anesthesia
* Arterial line in place for clinical care
* Able to provide informed consent
* Arterial and plethysmographic waveforms adequate for measurement
Exclusion Criteria
* Severe valvular heart disease or intracardiac shunt
* Pregnancy
* Severe right-heart failure or condition where a fluid bolus is unsafe
* Ongoing hemodynamic instability requiring rapid vasoactive titration at assessment
* Persistently unreliable arterial/pleth signals despite optimization
* Any situation the anesthesiologist judges that the fluid challenge is unsafe
19 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wonkwang University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Cheol Lee,MD,PhD,
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Cheolhyeong Lee, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Wonkwang University School of Medicine Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Wonkwang University School of Medicine Hospital
Iksan, Jeollabuk-do, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Cheol Lee, M.D.,Ph.D.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Wonkwang UH 22
Identifier Type: -
Identifier Source: org_study_id